(Q36727344)

15 August 2017

1 reference

title

A public health approach to cervical cancer control: considerations of screening and vaccination strategies (English)

1 reference

15 August 2017

0 references

cervix uterine cancer

1 reference

1

Sue Goldie

1 reference

15 August 2017

publication date

1 November 2006

1 reference

International Journal of Gynecology and Obstetrics

15 August 2017

published in

1 reference

15 August 2017

volume

94 Suppl 1

1 reference

15 August 2017

page(s)

S95-105

1 reference

Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Methods to assess the costs and health effects of interventions for improving health in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Cost-effective policies for cervical cancer screening. An international review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

The cost-effectiveness of cervical cancer screening for low-income elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Benefits and costs of using HPV testing to screen for cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Early withdrawal from cervical cancer screening: the question of cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

The planning of cervical cancer screening programmes in eastern Europe: is viral testing a suitable alternative to smear testing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Cost-effectiveness of cervical-cancer screening in five developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Costs and benefits of different strategies to screen for cervical cancer in less-developed countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Optimization of cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Mathematical models of the transmission and control of sexually transmitted diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Public health paradoxes and the epidemiological impact of an HPV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Modeling for health care and other policy decisions: uses, roles, and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Vaccination against multiple HPV types

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

The theoretical population-level impact of a prophylactic human papilloma virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2807%2960016-2

10.1016/S0020-7292(07)60016-2

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference